Chardan Capital Trims ProQR Therapeutics (NASDAQ:PRQR) Target Price to $20.00

ProQR Therapeutics (NASDAQ:PRQR) had its target price lowered by Chardan Capital from $25.00 to $20.00 in a report released on Tuesday, BenzingaRatingsTable reports. The firm currently has a buy rating on the biopharmaceutical company’s stock.

Several other analysts have also weighed in on the company. HC Wainwright reissued a buy rating and issued a $20.00 target price on shares of ProQR Therapeutics in a report on Tuesday, July 21st. Zacks Investment Research raised ProQR Therapeutics from a hold rating to a buy rating and set a $6.00 target price on the stock in a report on Saturday, May 9th. Finally, BidaskClub lowered ProQR Therapeutics from a hold rating to a sell rating in a report on Tuesday, July 7th. One investment analyst has rated the stock with a sell rating and five have assigned a buy rating to the company’s stock. ProQR Therapeutics has a consensus rating of Buy and a consensus target price of $21.50.

NASDAQ:PRQR traded up $0.09 during trading hours on Tuesday, hitting $5.34. The company’s stock had a trading volume of 1,260 shares, compared to its average volume of 187,784. The business’s 50-day moving average is $5.37 and its two-hundred day moving average is $6.02. The company has a market capitalization of $285.07 million, a PE ratio of -4.34 and a beta of 0.45. The company has a debt-to-equity ratio of 0.06, a quick ratio of 10.09 and a current ratio of 10.09. ProQR Therapeutics has a 52-week low of $4.46 and a 52-week high of $10.98.

ProQR Therapeutics (NASDAQ:PRQR) last posted its earnings results on Thursday, August 6th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.31) by $0.23. As a group, analysts predict that ProQR Therapeutics will post -1.38 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. RTW Investments LP boosted its stake in shares of ProQR Therapeutics by 2.6% during the second quarter. RTW Investments LP now owns 4,902,785 shares of the biopharmaceutical company’s stock valued at $29,809,000 after acquiring an additional 123,650 shares during the last quarter. Jennison Associates LLC boosted its stake in ProQR Therapeutics by 0.5% in the 2nd quarter. Jennison Associates LLC now owns 2,625,514 shares of the biopharmaceutical company’s stock worth $15,963,000 after buying an additional 13,208 shares during the last quarter. DAFNA Capital Management LLC boosted its stake in ProQR Therapeutics by 11.1% in the 1st quarter. DAFNA Capital Management LLC now owns 1,237,400 shares of the biopharmaceutical company’s stock worth $6,793,000 after buying an additional 123,400 shares during the last quarter. Kerrisdale Advisers LLC boosted its stake in ProQR Therapeutics by 1.2% in the 2nd quarter. Kerrisdale Advisers LLC now owns 453,182 shares of the biopharmaceutical company’s stock worth $2,755,000 after buying an additional 5,525 shares during the last quarter. Finally, Cowen AND Company LLC boosted its stake in ProQR Therapeutics by 242.1% in the 1st quarter. Cowen AND Company LLC now owns 354,849 shares of the biopharmaceutical company’s stock worth $1,948,000 after buying an additional 251,122 shares during the last quarter. 58.98% of the stock is currently owned by institutional investors and hedge funds.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biopharmaceutical company, engages in the discovery and development of RNA-based therapeutics for the treatment of genetic disorders. Its lead product candidates include eluforsen, a RNA-based oligonucleotide used for the treatment of cystic fibrosis; QR-110, an oligonucleotide that is designed to treat Leber's congenital amaurosis; QR-313, a dermatology candidate for the treatment of epidermolysis bullosa; and QR-421a and QR-411 to treat type 2A Usher syndrome.

Read More: What is a dead cat bounce?

Receive News & Ratings for ProQR Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProQR Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.